Urine Biomarkers for Bladder Cancer

Children's Hospital Boston
posted on 11/26/2009

Bladder cancer is the second most common genitourinary cancer in the US. Using proteomics and antibody-based approaches, Dr. Zetter and colleagues found elevated levels of Cystatin B, a cathepsin protease inhibitor, in tissue and urine of bladder cancer patients compared to controls, and demonstrated a positive correlation between levels of Cystatin B and tumor grade, stage and shorter time to disease recurrence and progression.

Innovation Details

File Number: CMCC 1337

Web site: http://www.childrensinnovations.org/SearchDetai...

Other Information: *Investigator(s)*
Bruce Zetter

*Contact*
Maude Tessier, Maude.Tessier@childrens.harvard.edu

IP Protection

License Online

This innovation currently is not available for online licensing. Please contact David Altman at Children's Hospital Boston for more information.

request more info